Akero Therapeutics, Inc. (0K4.F)

21,30 +0,03 (+0,14%) Börsenschluss: 04:44PM CEST

Akero Therapeutics, Inc.

601 Gateway Boulevard
Suite 350
South San Francisco, CA 94080
United States
650 487 6488
https://akerotx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 58

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Andrew Cheng M.D., Ph.D.	President, CEO & Director	966,7k	14,25M	1967
Dr. Jonathan M. Young J.D., Ph.D.	Co-Founder, Executive VP, COO & Secretary	627,25k	545,15k	1970
Dr. Timothy Rolph	Co-Founder & Chief Scientific Officer	673,86k	2,01M	1954
Mr. William R. White J.D.	Executive VP, CFO, Treasurer & Head of Corporate Development	632,58k	783,51k	1973
Ms. Catriona Yale	Executive VP & Chief Development Officer	632,58k	428,12k	1972
Mr. Scott A. Gangloff	Chief Technical Officer	N/A	N/A	1974
Mr. David West J.D.	Vice President of Legal	N/A	N/A	N/A
Mr. John J. Schembri	VP & Head of Finance	N/A	N/A	1962
Mr. Patrick Lamy	Senior Vice President of Commercial Strategy	N/A	N/A	1973

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Corporate Governance

Akero Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 8. Die grundlegenden Scores sind Audit: 3, Vorstand: 9, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.